NCT06307262 European Registry of Transcatheter Repair for Tricuspid Regurgitation
| NCT ID | NCT06307262 |
| Status | Recruiting |
| Phase | — |
| Sponsor | LMU Klinikum |
| Condition | Tricuspid Regurgitation |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2023-10-23 |
| Primary Completion | 2030-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2023-10-23 with a primary completion date of 2030-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To investigate clinical and survival outcomes following transcatheter tricuspid valve repair or replacement.
Eligibility Criteria
Inclusion Criteria: * Patients treated with one of the following transcatheter devices for TV repair or replacement: PASCAL, TriClip, TricValve, Evoque, LuX-Valve * Age ≥ 18 years
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06307262 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Tricuspid Regurgitation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06307262 currently recruiting?
Yes, NCT06307262 is actively recruiting participants. Contact the research team at Joerg.Hausleiter@med.uni-muenchen.de for enrollment information.
Where is the NCT06307262 trial being conducted?
This trial is being conducted at Munich, Germany.
Who is sponsoring the NCT06307262 clinical trial?
NCT06307262 is sponsored by LMU Klinikum. The trial plans to enroll 3,000 participants.